CION Ameerpet
An oligodendroglioma is a slow-growing glioma defined by an IDH mutation and a 1p/19q co-deletion. This page explains what it is, how it is diagnosed and treated, and what the outlook looks like.
An oligodendroglioma is a type of glioma — a brain tumour that starts in the brain itself. It arises from oligodendrocytes, the glial cells whose job is to make the insulating myelin coating around the brain's nerve fibres. Oligodendrogliomas are usually found in the cerebral hemispheres, most often in the frontal lobe, and tend to be slow-growing.
What makes an oligodendroglioma distinctive is its molecular signature. Under the 2021 WHO classification, the diagnosis requires two molecular features together: an IDH mutation and a 1p/19q co-deletion. A tumour is only a true oligodendroglioma if it carries both. That same biology is good news — these tumours are among the most treatment-responsive gliomas. This page sits within our wider brain cancer & tumour hub and explains, in plain language, what an oligodendroglioma is, how it is graded, diagnosed and treated, and what the outlook looks like.
Under the 2021 WHO classification of brain tumours (reflected in NCCN and EANO guidance), a tumour can only be called an oligodendroglioma if it carries both an IDH mutation and a 1p/19q co-deletion. The 1p/19q co-deletion is not just a label — it identifies a tumour that responds particularly well to chemotherapy and radiation and has a more favourable outlook than other gliomas of the same grade. This is exactly why two tumours that look similar under the microscope can be classified, and treated, very differently — and why molecular testing should be part of the standard work-up for every malignant glioma.
Like other gliomas, oligodendrogliomas are given a WHO grade rather than a Stage I–IV number. There are two grades — and the grade, together with the IDH and 1p/19q results, tells your team how the tumour is likely to behave.
The slower-growing form, and the more common of the two. Grade 2 oligodendrogliomas can grow over years and are often first noticed because of a seizure. Many people live well for a long time. Treatment usually involves maximum safe surgery, sometimes followed by radiation and chemotherapy, or careful monitoring for small, fully removed tumours.
The faster-growing (anaplastic) form. The tumour cells look more aggressive under the microscope, so treatment is more intensive — typically surgery followed by radiation and chemotherapy. Because these tumours still carry the IDH mutation and 1p/19q co-deletion, they remain among the more treatment-responsive high-grade gliomas.
Oligodendrogliomas are most common in adults aged 30–50 — younger on average than people with glioblastoma. They are uncommon overall, making up a minority of all gliomas, which is one reason an accurate, molecularly confirmed diagnosis from an experienced team matters.
Within the glioma family, oligodendrogliomas sit at the more favourable end. They are distinct from astrocytomas (which lack the 1p/19q co-deletion) and grow far more slowly than glioblastoma. The molecular result is what separates them.
Because oligodendrogliomas grow slowly and often sit in the frontal lobe, symptoms can build gradually over months or years. Importantly, none of these symptoms means a tumour on its own — most headaches, and many seizures, have other, more common causes. What matters is a symptom that is new, persistent and progressive. The single most common first sign of an oligodendroglioma is a seizure.
Red flag: a first adult seizure, or new one-sided weakness, speech loss or sudden vision change that is persistent and progressive, always warrants an urgent brain MRI. Speak to a CION neuro-oncologist if you or a loved one has these signs.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centreTravelling for treatment? We may have a centre right where you are.
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationShare your name and number — we'll call you back within 30 minutes to schedule your consultation.
Whether you want to understand your MRI, confirm the IDH and 1p/19q results, or get a second opinion before treatment — CION's neuro-oncology team is here to help, with same-week appointments.
Diagnosing an oligodendroglioma takes more than a single scan. The pathway confirms the tumour, identifies its grade, and — crucially — reads the two molecular markers that actually define the diagnosis, so the right treatment can be chosen from the start.
An MRI with contrast is the gold standard for finding and characterising an oligodendroglioma. It shows the tumour's location, size and its relationship to critical brain areas, and reveals features that suggest its grade — oligodendrogliomas sometimes show calcification (tiny calcium deposits) on imaging, a clue but not a confirmation. Imaging can only suggest an oligodendroglioma; it cannot confirm the exact type or molecular profile. You can learn more on our contrast MRI for brain tumours page.
Only a tissue sample confirms an oligodendroglioma and its grade. Tissue is obtained either during surgical removal of the tumour or, for deep or risky locations, via a stereotactic needle biopsy. Both the biopsy and any neurosurgery are coordinated with accredited neurosurgical partners; CION manages the diagnosis, the molecular testing, and the treatment that follows.
This is where an oligodendroglioma diagnosis is truly made. Two markers from the tumour tissue do the work. An IDH mutation is the single most powerful prognostic marker in glioma — IDH-mutant tumours grow more slowly and have a better outlook than IDH wild-type tumours of the same grade. The 1p/19q co-deletion is what separates an oligodendroglioma from an astrocytoma: it identifies a tumour that responds particularly well to chemotherapy and radiation. A tumour is only diagnosed as an oligodendroglioma when both are present. The 2021 WHO classification (per NCCN and EANO guidance) is built around exactly these markers — which is why grade alone no longer tells the full story. CION arranges IDH and 1p/19q testing as standard on every malignant glioma sample. For a deeper look, see our 1p/19q co-deletion and oligodendroglioma page, and our overview of molecular testing for brain tumours.
The 1p/19q co-deletion means part of two chromosomes — the short arm of chromosome 1 and the long arm of chromosome 19 — have been lost together. According to NCCN and EANO guidance, IDH-mutant, 1p/19q co-deleted oligodendrogliomas are among the most treatment-responsive gliomas and tend to have a more favourable outlook than other gliomas of the same grade. This single test result genuinely changes both the diagnosis and the treatment plan — so if it has not been arranged on a glioma sample, it is worth asking for before treatment begins.
There is no single treatment for "an oligodendroglioma" — the plan depends on the grade, the molecular profile, your symptoms, and how much of the tumour can be safely removed. What stays the same is that CION reviews every case at a multidisciplinary tumour board before any plan is finalised, and coordinates each step as one continuous journey.
What CION delivers directly: radiation therapy (IMRT/IGRT), systemic drug therapy, imaging and diagnosis, molecular testing, steroid and seizure management, and supportive and rehabilitation care. Specialist radiosurgery and neurosurgery are arranged through coordinated, accredited partners. For the full picture, see our brain tumor treatment in Hyderabad page.
One of the most reassuring things about an oligodendroglioma is that it sits at the more favourable end of the glioma spectrum. The same IDH mutation and 1p/19q co-deletion that define the tumour also point to a better outlook than other gliomas of the same grade. Published guidance from NCCN and EANO reports survival for IDH-mutant, 1p/19q co-deleted oligodendrogliomas in years rather than months — with many people, especially those with Grade 2 tumours, living well for a long time.
It is important to hold these numbers gently. They are ranges drawn from large groups of patients, not promises about any one person. Your own outlook depends on the grade, your age, how much of the tumour was safely removed, and how it responds to treatment. There is no single headline survival figure that fits every oligodendroglioma. What we can say is that the molecular biology of these tumours is genuinely encouraging, and that careful, coordinated treatment makes a real difference.
For more on how grade and biology shape outlook across brain tumours, see our pages on low-grade glioma and IDH mutation in glioma.
An oligodendroglioma diagnosis raises a lot of questions, and it is normal to feel overwhelmed. You deserve time to understand what is happening and to feel confident in the plan. At CION, every case is reviewed by a tumour board — surgery, radiation and medical oncology deciding together — and we make decisions for healing, not billing, with transparent costs explained up front. We walk this journey with you, from the first scan through long-term follow-up.
A second opinion is particularly worthwhile in three situations:
To go deeper, read about the 1p/19q co-deletion that defines this tumour, the wider glioma family, and astrocytoma for comparison. You can also explore our broader brain tumor treatment in Hyderabad page.
Ready to talk it through? Book a free consultation or call 18002028726 — we'll walk this journey with you.
Get a free written second opinion from CION's neuro-oncology tumour board — especially valuable before treatment begins, or if IDH and 1p/19q molecular testing hasn't yet been arranged.
These aren't paid endorsements or written reviews. These are video testimonials from real patients and families — recorded on their own phones, in their own words. Pick any one. Watch it. Then decide.
Read all 800+ reviews on Google
Start Your Story. Book Free Consultation.An oligodendroglioma is a type of glioma — a brain tumour that starts in the brain itself. It arises from oligodendrocytes, the glial cells that make the insulating myelin coating around nerve fibres. Under the 2021 WHO classification, the diagnosis is defined by two molecular features together: an IDH mutation and a 1p/19q co-deletion. A tumour is only a true oligodendroglioma if it carries both. Oligodendrogliomas tend to grow slowly and are among the most treatment-responsive gliomas, which is why an accurate molecular diagnosis matters so much.
An oligodendroglioma is a malignant brain tumour, but it is one of the more favourable gliomas in how it behaves. Rather than the Stage I–IV system used for most cancers, brain tumours are given a WHO grade. Oligodendrogliomas are either Grade 2 (slower-growing) or Grade 3 (anaplastic, faster-growing). Even so, both are slow compared with glioblastoma, and many people live for many years with the right treatment. The grade, together with the IDH and 1p/19q results, tells your team how the tumour is likely to behave and shapes the whole plan. The exact grade is confirmed only by tissue, not by a scan alone.
The 1p/19q co-deletion is the defining feature of an oligodendroglioma — and it is also a powerful piece of good news. It means that part of two chromosomes (the short arm of chromosome 1 and the long arm of chromosome 19) have been lost together. Tumours with this co-deletion, alongside an IDH mutation, respond particularly well to chemotherapy and radiation and tend to have a more favourable outlook than other gliomas of the same grade. Because the result genuinely changes both the diagnosis and the treatment plan, CION arranges 1p/19q testing as standard. Read more on our 1p/19q co-deletion and oligodendroglioma page.
Diagnosis usually begins with an MRI of the brain with contrast, which shows the tumour's location, size and features that suggest its grade. However, imaging can only suggest an oligodendroglioma — a tissue sample (biopsy) is essential to confirm it. The sample is examined under the microscope and tested for the two markers that define the tumour: IDH mutation and 1p/19q co-deletion. At CION, biopsy and any neurosurgery are coordinated with accredited neurosurgical partners, while we manage the imaging, molecular testing, radiation and systemic therapy directly. An accurate molecular diagnosis is what allows the treatment plan to fit your exact tumour.
Treatment depends on the grade, the molecular profile, your symptoms, and how much of the tumour can be safely removed. The usual first step is maximum safe surgical removal, coordinated with accredited neurosurgical partners. After surgery, many oligodendrogliomas are treated with radiation followed by chemotherapy, because 1p/19q co-deleted tumours respond so well to this combination; some small, low-grade tumours that have been completely removed may instead be watched closely with regular MRI scans. CION delivers the radiation (IMRT/IGRT), the systemic drug therapy, the molecular testing and the supportive care directly. Every case is reviewed by a multidisciplinary tumour board first. For the full picture, see our brain tumor treatment in Hyderabad page.
Oligodendrogliomas are among the more favourable gliomas, and outcomes are generally better than for other gliomas of the same grade — largely because of the IDH mutation and 1p/19q co-deletion that define them. Published guidance from NCCN and EANO reports survival for IDH-mutant, 1p/19q co-deleted oligodendrogliomas in years rather than months, with many people living well for a long time, especially with Grade 2 tumours. That said, outcomes vary a great deal from person to person depending on grade, age, the extent of surgery and how the tumour responds. These are ranges, not promises — your own outlook is best discussed with your neuro-oncology team after the full molecular results are in.
Yes — oligodendrogliomas can recur after treatment, and a Grade 2 tumour can transform into a higher-grade (Grade 3) tumour over time. This is why long-term surveillance MRI is an important part of care even when a tumour is responding well. Regular scans let your team spot any change early, while there are still good options. If a tumour recurs or progresses, further surgery, additional radiation or systemic therapy may be considered, again decided by the tumour board. CION manages this ongoing monitoring and supportive care directly, so your follow-up is one continuous journey rather than a series of disconnected appointments.
Browse our complete guide to brain tumours and brain cancer — symptoms, scans, tumour types, treatment, prognosis and life after treatment. Tap any topic to read more.